Phaseline

Targets › CGAS

CGAS (Cyclic GMP-AMP synthase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Apr 2029.

Nucleotidyltransferase that catalyzes the formation of cyclic GMP-AMP (2',3'-cGAMP) from ATP and GTP and plays a key role in innate immunity. Catalysis involves both the formation of a 2',5' phosphodiester linkage at the GpA step and the formation of a 3',5' phosphodiester linkage at the ApG step, producing c[G(2',5')pA(3',5')p]. Acts as a key DNA sensor: directly binds double-stranded DNA (dsDNA), inducing the…. (UniProt, Q8N884)

Open in Phaseline: the race on CGAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese PLA General HospitalManganese Chloride
cGAS-STING pathway activator
CGAS, STING1Phase 3Ovarian CancerApr 2029

Conditions

Ovarian Cancer (1)

Modalities

mixed (1)

Companies

Chinese PLA General Hospital (1)

Related targets

STING1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.